Vicore Pharma is a pharmaceutical company based in Stockholm that specializes in the development of Angiotensin II Type 2 Receptor Agonists (ATRAGs). The company is actively engaged in research and development aimed at creating innovative drug therapies, with a particular focus on addressing health conditions such as idiopathic pulmonary fibrosis (IPF). Vicore Pharma conducts clinical trials, including the phase 2a AIR trial, to evaluate the efficacy and safety of its therapeutic candidates.
In addition to its clinical research, Vicore Pharma provides a range of informational resources, including webinars that discuss trial results and the mechanisms of its drugs. The company also publishes financial reports and press releases to keep stakeholders informed about its activities and developments. Furthermore, Vicore Pharma participates in events related to advancements in the pharmaceutical field, emphasizing its commitment to advancing medical science through rigorous research and the exploration of new therapeutic potentials.